Infinity Pharmaceuticals (INFI) : Rubric Capital Management has sold out all of its stake in Infinity Pharmaceuticals during the most recent quarter, according to the disclosure filed by the company on Nov 14, 2016 with the SEC. The investment management company has sold out 125,000 shares of Infinity Pharmaceuticals which is valued at $166,250.
Other Hedge Funds, Including , Parametric Portfolio Associates added INFI to its portfolio by purchasing 19,355 company shares during the most recent quarter which is valued at $25,742. Spark Investment Management sold out all of its stake in INFI during the most recent quarter. The investment firm sold 53,700 shares of INFI which is valued $68,736.
Infinity Pharmaceuticals opened for trading at $1.21 and hit $1.23 on the upside on Monday, eventually ending the session at $1.23, with a gain of 1.65% or 0.02 points. The heightened volatility saw the trading volume jump to 3,62,641 shares. Company has a market cap of $61 M.
On the company’s financial health, Infinity Pharmaceuticals reported $-0.39 EPS for the quarter, beating the analyst consensus estimate by $ 0.46 according to the earnings call on Nov 9, 2016. Analyst had a consensus of $-0.85.Analysts expectations of $ 7.27.During the same quarter in the previous year, the company posted $0.84 EPS.
Infinity Pharmaceuticals Inc. is a biopharmaceutical company that is engaged in the discovery development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target emerging disease pathways for potential applications in oncology. Its most advanced product candidate is duvelisib also known as IPI-145 an oral dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K) for the treatment of hematologic malignancies. In addition to duvelisib the Company seeks to expand its pipeline through internal discovery research program and licensing of potential new product candidates or technologies discovered by third parties. The Company is conducting DUETTS (Duvelisib Trials in Hematologic Malignancies) a worldwide investigation of duvelisib in blood cancers.